Lightstone Ventures

We’re excited to welcome Joe Zakrzewski as the Chair of our #BoardOfDirectors. A 30-year biotech and pharma veteran, we look forward to leveraging Joe’s expertise and insights as we continue to advance the clinical development of our investigational #GeneTherapies for #InheritedRetinalDiseases.   Read more in our press release: https://lnkd.in/eagg7tES   Image description: A picture of Mr. Zakrzewski is on the left. Text on the right reads “Atsena Therapeutics Appoints Joseph S. Zakrzewski as Board Chair.” The Atsena Therapeutics logo is in the bottom right corner.

https://lnkd.in/g45DKpKk

Amber Tx successfully closes a $100 million Series A financing to advance breakthrough Amber-UI neuromodulation therapy for mixed urinary incontinence towards US FDA approval. US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI). Amber-UI has the unique potential to treat the millions of women who suffer from both urge and stress incontinence with a singular adaptive therapy. Read the full press release and learn more about our therapy approach on our website: https://lnkd.in/eZ7XthCy

#Alchemab today announces that it has been awarded a grant of US$595,000 by The Michael J. Fox Foundation for Parkinson's Research (MJFF)!   The grant will fund research performed at Alchemab following its identification of antibodies that target prostaglandin biology in #Parkinsonsdisease, a potentially unique approach to treatment.   Click the link in the comments below to read the press release and learn more about Alchemab's #Parkinsons disease program.   #biotech #lifesciences #antibodies #neuroscience

We are excited to unveil new clinical results as part of #ASCO24, highlighting that our HLA-G-targeted #immunotherapy generated promising clinical activity in patients with biomarker-defined advanced #colorectalcancer and #headandneckcancer. The full results will be presented during a poster session on June 1 at 9:00 a.m. CDT. Check out the data in our press release: https://lnkd.in/g5T2PkU4

The #Nimbi team is looking forward to attending the American Society of Clinical Oncology (ASCO) Annual Meeting next week. Marcus Noel, M.D., will present new positive monotherapy data from a Phase 1/2 trial evaluating our investigational HPK1 inhibitor in the treatment of advanced solid tumors. https://lnkd.in/e7_RE_7A #ASCO24

🎉 The wait is over: the TAILORED-AF results are out! TAILORED-AF trial findings demonstrated superiority in freedom from atrial fibrillation #AF with or without anti-arrhythmic drugs at 12 months from a tailored cardiac ablation guided by artificial intelligence #AI when compared to pulmonary vein isolation (PVI) alone. Learn more about the results : https://lnkd.in/eHCeAbjc *The clinical significance of utilizing the Volta AF-Xplorer™ software for catheter ablation of atrial arrhythmias has not been reviewed by the FDA. #EPeeps #electrophysiology #Afib

We are excited to share data from the first cohort of the LIGHTHOUSE study, our ongoing Phase I/II clinical trial evaluating our investigational #GeneTherapy ATSN-201 for the treatment of X-linked retinoschisis (#XLRS). For the first time in patients, we have validated the ability of AAV.SPR, our novel spreading #capsid, to spread laterally well beyond the subretinal injection blebs. Additionally, we have demonstrated the ability to safely administer subretinal injections in patients with extensive retinal schisis. Subretinal injection of ATSN-201 was well tolerated in all three patients in the first cohort with two patients showing extensive resolution of schisis beginning at 8 weeks after dosing. Additional and continued resolution of schisis was observed through week 24, the latest time point available. Read more about the data in our press release: https://lnkd.in/eAcpdUHS

We are pleased to announce the addition of $47M to our Series B-1 Extension! These funds will advance CVN424, our first-in-class, non-dopamine therapy for the treatment of Parkinson’s into a Phase 3 clinical trial. Furthermore, they will support our robust pipeline of precision CNS treatments. To learn more, read our press release: https://lnkd.in/g-TyntMw